Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Trader X who wrote (13671)	5/6/1998 3:22:00 PM
From: Postman	Respond to of 17305

ALYA OTC BB is looking good, hit $1.60 last week and came back to $1.22, now on the way back up. They just hired a very successful director of marketing. Here's the latest news, more news due on Thursday... __________________________________________________________________ Tuesday May 5, 10:44 am Eastern Time Company Press Release Gerry Gabel Appointed Director of Business Development of ALYA ALYA Opens Sales Office in Austin, Texas PALO ALTO, Calif.--(BUSINESS WIRE)--May 5, 1998--ALYA International, Inc. (''ALYA'' or the ''Company'')(OTC BB:ALYA - news) announced today that Gerry Gabel, formerly with the Echelon Corporation, has joined ALYA as Director of Business Development (USA). Gabel's mission is to use his years of very successful sales and management experience and his multiple contacts in the building automation industry to build a network of resellers across the United States. Gabel brings to ALYA 22 years of experience in sales and management in the high tech industry. He has been with Echelon since 1991. Gabel's previous sales and management positions were with the Exabyte Corporation [Nasdaq:EXBT - news], Pixar and Data General where he accomplished the following: Echelon Consistent revenue increases since 1991. Penetrated 15 "Fortune 500" companies as Strategic Accounts Manager; Exabyte Corp. Responsible for $23 million in revenue as National Distribution Sales Manager; Pixar Increased profitability by 17%. And managed relationships with Sun Microsystems, Silicon Graphics, Digital Equipment Corporation [NYSE:DEC - news] and IBM. Data General Sold over $25 million in Data General equipment. "Salesman of the Year" in 1984. With the appointment of Gable, ALYA has established an office in Texas at: 1150 Lakeway Drive Telephone: 512/261-2077 Austin Texas 78734 Fax: 512/261-2111 USA ALYA International, Inc. (OTC BB:ALYA - news) is a leader in software design using Microsoft's(R) Windows NT(R), Echelon's(R) LonWorks(R) technology and Local/Wide area networks communication protocols. ALYA's first product, O.P.E.N.cortex(tm) is a development platform based on these de facto standards directed to companies implementing applications for end users such as building management systems and process control applications. ALYA has utilized this platform in the design of its second product O.P.E.N.centrix(tm), an application for Security Systems and Building Access. LonWorks technology is a de facto standard in the building automation and process control industries providing a new standard for open architecture and interoperable control systems. The LonMark(R) Association, supported by Motorola(R), Honeywell Inc [NYSE:HON - news].(R), Johnson Controls, Inc.(R), Olivetti(R), BTE(R) and Toshiba Corporation(R) endorses LonWorks. ALYA is one of the first companies to develop ''plug and play'' open architecture (ALYA's O.P.E.N.(tm) ''Open Platform for Essential Networks'') hardware and software for the security and control industries.

To: Trader X who wrote (13671)	5/6/1998 3:46:00 PM
From: Jeffrey S. Mitchell	Respond to of 17305

Check out this article about ENMD (courtesy of Nero on the ENMD thread): biz.yahoo.com Key quote: "It's early data that hasn't been confirmed by other laboratories. And tests in humans are over a year away,'' Gordon said, noting EntreMed officials have said initial clinical trials in people would begin within 12 to 18 months. - Jeff

To: Trader X who wrote (13671)	5/6/1998 4:04:00 PM
From: nigel bates	Respond to of 17305

<<The UK is beginning tests on humans on a competitive drug in 6 months, and this should speed things up for ENMD>> I'm not sure this is a relevant factor. There are a few other biotechs with the same approach (anti-angiogenesis) who already have compounds in clinical trials (eg SUGN). The point with ENMD is the exceptional results in mice - ie 100% apparently, and that the compounds are natural human proteins. It remains a long shot, like all biotechs with compounds at so early a stage, but might be worth a punt @ 20ish. I would recommend waiting before buying as the herd is not patient, and a few months without big news should give a sub 20 entry point. Kind Regards Nig